A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05885555
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Cente, Boston, Massachusetts, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Completed
- Conditions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17517
- Registration Number
- NCT05874817
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Adherence and Persistence to Inclisiran Among Early Users in Germany
Completed
- Conditions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1109
- Registration Number
- NCT05870657
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05870709
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05870579
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05868629
- Locations
- 🇺🇸
Duke Clinical Research Institute ., Durham, North Carolina, United States
Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05857748
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
Completed
- Conditions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT05853432
- Locations
- 🇮🇪
Novartis Pharmaceuticals, Dublin, Ireland
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT05853458
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerselen, Germany
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 467
- Registration Number
- NCT05853445
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
© Copyright 2024. All Rights Reserved by MedPath